Two interesting pieces either written by H.M. Pharma Consultancy or citing it have become publicly available during the past two weeks. First, the launch issue of Pharmaceutical Patent Analyst, the new journal from the Future Science Group, is already online and with it the first issue of our Patent Highlights (see here), which will be published in every bimonthly issue until at least January 2013. The entire launch issue of the journal is free and everyone is invited to peruse the contents. Later issues will be subscription-only. For those interested in drug repurposing the piece by Julian Cockbain, “Patent protection in Europe of pharmaceuticals found to have a further medical indication,” might be of particular interest (see here).
The February/March issue of Wiley Publishers’ Pharmaceutical Formulation & Quality which just went online carries a piece titled “Patents Offer Clues into Developments in Ocular Delivery – Austrian consulting firm keeps track of ophthalmologic advances“(here). Thanks, Neil Canavan and whoever else made this December 2011 interview go online. It a satisfying acknowledgement for our efforts to build a first patentome— in this case, the entirety of patent information with relevance for ocular pharmacology, tissue technology and diagnostics. In other words, the REDWING module of our THIRDSPACEdatabase project. By the way, REDWING had 148,129 fully corrected patent pages when we last locked the database on March 4. A total of 5,110 patent documents have been identified and logged. As this work proceeds, we are considering ways to crowdsource this work.
There is of course more publishing already in the pipeline. The Patent Highlights for the May issue of the Pharmaceutical Patent Analyst are set and done (these pieces are being produced on a rolling schedule), and last week we settled the peer review issues for a review summarizing the developments in the less common fields of ocular patenting. All that has to happen on top of the work we are doing for our clients, obviously. Stay tuned!